RAN-QUINAPRIL TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
30-06-2017
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
QUINAPRIL (QUINAPRIL HYDROCHLORIDE)
から入手可能:
RANBAXY PHARMACEUTICALS CANADA INC.
ATCコード:
C09AA06
INN（国際名）:
QUINAPRIL
投薬量:
40MG
医薬品形態:
TABLET
構図:
QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40MG
投与経路:
ORAL
パッケージ内のユニット:
30/1000
処方タイプ:
Prescription
治療領域:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
製品概要:
Active ingredient group (AIG) number: 0123206004; AHFS:
認証ステータス:
APPROVED
承認日:
2014-10-17
製品の特徴
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
RAN
™
-QUINAPRIL
QUINAPRIL TABLETS USP
(5 MG, 10 MG, 20 MG AND 40 MG OF QUINAPRIL AS QUINAPRIL HYDROCHLORIDE)
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
June 22, 2017
CONTROL NO. 206533
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_Pr_
_RAN™-QUINAPRIL (Quinapril Tablets USP) Product Monograph_
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
15
DOSAGE AND ADMINISTRATION
................................................................................
18
OVERDOSAGE
...................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION ANDPACKAGING
................................................. 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
24
PHARMACEUTICAL INFORMATION
......................
完全なドキュメントを読む
